Concurrent Investment Advisors LLC Reduces Position in GSK plc (NYSE:GSK)

Concurrent Investment Advisors LLC lessened its holdings in shares of GSK plc (NYSE:GSK) by 30.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,138 shares of the pharmaceutical company’s stock after selling 5,831 shares during the period. Concurrent Investment Advisors LLC’s holdings in GSK were worth $444,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. FMR LLC boosted its holdings in shares of GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after purchasing an additional 2,224,345 shares during the period. Fisher Asset Management LLC boosted its holdings in shares of GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after purchasing an additional 870,449 shares during the period. Hotchkis & Wiley Capital Management LLC boosted its holdings in shares of GSK by 30.8% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after purchasing an additional 833,080 shares during the period. Miller Howard Investments Inc. NY purchased a new stake in shares of GSK in the fourth quarter valued at approximately $23,366,000. Finally, Bridgewater Associates LP boosted its holdings in shares of GSK by 107.3% in the third quarter. Bridgewater Associates LP now owns 965,836 shares of the pharmaceutical company’s stock valued at $39,483,000 after purchasing an additional 500,010 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Morgan Stanley assumed coverage on GSK in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Finally, Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Seven investment analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Stock Performance

Shares of NYSE:GSK opened at $37.03 on Tuesday. The company has a market capitalization of $76.74 billion, a price-to-earnings ratio of 23.29, a price-to-earnings-growth ratio of 1.12 and a beta of 0.64. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.92. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The firm has a 50 day moving average of $34.67 and a 200 day moving average of $37.32.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. On average, sell-side analysts predict that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be given a dividend of $0.3932 per share. The ex-dividend date of this dividend is Friday, February 21st. This is an increase from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.25%. GSK’s dividend payout ratio is presently 98.74%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.